Page last updated: 2024-11-05

triazolam and Abstinence Syndrome, Neonatal

triazolam has been researched along with Abstinence Syndrome, Neonatal in 1 studies

Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Attallah, A1
Seilanian, M1
Bavoux, F1
Choisy, H1

Other Studies

1 other study available for triazolam and Abstinence Syndrome, Neonatal

ArticleYear
[Psychotropics and pregnancy. Apropos of 2 case reports: the dose of triazolam].
    Revue francaise de gynecologie et d'obstetrique, 1989, Volume: 84, Issue:1

    Topics: Apnea; Female; Half-Life; Humans; Infant, Newborn; Male; Neonatal Abstinence Syndrome; Pregnancy; Pr

1989
chemdatabank.com